Skip to Content

Basilea Pharmaceutica Ltd BSLN Stock Quote

| Rating as of

Morningstar‘s Stock Analysis BSLN

Valuation
Currency in CHF
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics BSLN

Company Profile BSLN

Business Description

Basilea Pharmaceutica Ltd is a biotechnology company that focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections, and oncology. The company aims to develop drugs in order to target the medical challenge of resistance and non-response to current treatment options. The company's research strategy integrates the areas of genomics, cell biology, medicinal chemistry, and pharmacology. Its commercial product comprises of Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections.

Contact
Grenzacherstrasse 487
Basel, 4058, Switzerland
T +41 616061111
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Dec 31, 2022
Employees 177